Tagged with RNA

Turkey Turkey – home to an 80 million-strong population, a substantial pharmaceuticals market and a universal healthcare system that is the envy of its neighbours – stands as one of the most promising healthcare and life science investment destinations in its region. Topics covered in this report range from the successes…

France Arnaud Gobet, president of Innothera, discusses how the company balances its unique and diverse offering of medical devices, hygiene and protection products and pharmaceuticals, Innothera’s burgeoning international footprint and the condition of France’s industrial environment.   In the long term, we see the suppression of the ISF (solidarity tax on…

Turkey Imports and exports in Turkish pharma between 2010 and 2017. Pharmaceutical exports grew to a total of USD 898 million in 2017.   These charts show both the volume and value of imported and locally-produced drugs in the Turkish pharma market between 2010 and 2017. TL 13.33 billion (USD 2.57…

Spain Staffan Schüberg, CEO of Esteve, highlights the restructure of the company as it moves towards its new age of being a truly innovative pharmaceutical company on a global level. Furthermore, he highlights the international strategy and the role the US market will play in the future, as well as his…

Turkey Seizing the cost competitiveness of the Turkish market and the government’s nurturing of local manufacturing, Turkish companies are looking to harness their geographic positioning and export to developed and developing markets alike.   We did not shy away from entering the most advanced healthcare ecosystems. Barış Özyurtlu, General Manageger, Berko Ilac.…

Turkey Philipp Haas, chairman and CEO of DEVA, discusses the company’s export strategy and current positioning in the international pharmaceutical playing field. Haas also covers the changing dynamics of the industry in the Turkish market. In crisis there is opportunity for those who are willing to take it 2018 has been…

Spain Oriol Segarra, CEO of Uriach, describes the Spanish OTC company’s recent developments and transformation from a domestic organization to a truly European player.   These are very interesting times for Uriach; the company is celebrating its 180th anniversary, has just won OTC company of the year, and has invested in…

Malaysia Ch’ng Kien Peng, executive director of Xepa-Soul Pattinson, offers insights on the dynamic healthcare industry in Malaysia and the new government’s key role in supporting the local industry. He also details Xepa-Soul Pattinson’s strong footprint in the country as well as the company’s geographic expansion plans outside of Malaysia.  …

Algeria Noureddine Issad, general manager of Dar Al Dawa Algeria & Medi Pharma International unveils his ambitions to establish Dar Al Dawa as a major player in the Algerian market through local production of previously untapped product areas and discusses the new position of generics in the Algerian health industry.  …

Turkey Hasan Ulusoy, chairman of Nobel Ilac, elaborates on his company’s tremendous successes in Turkey and how they have differentiated themselves through early investment in biotechnology and firmly grasping international opportunities. Ulusoy also highlight’s Nobel’s vision for 2023 and their global ambitions. Alongside hospital products, biologicals are the next big opportunity…

Algeria Essam Farouk, President of MS Pharma provides insights on the success of its local manufacturing operations in Algeria, and the country’s potential to become an export hub. What recent changes have taken place within the MS Pharma group? We are planning expansions both inside and outside the Middle East and…

Spain Reig Jofre’s Ignasi Biosca outlines recent changes at the Spanish family-owned company, preserving its original ethos, portfolio development and internationalization plans. Can you update us on some of the recent changes at Reig Jofre? “The family still maintains 72 percent of the shares of the company so the original corporate…